Overview

Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2032-04-30

Target enrollment:

Participant gender:

Summary

This is a prospective, single-center, single-arm study on the combination regimen of irinotecan liposome, capecitabine and enronsubemab embedded in short-course radiotherapy as neoadjuvant therapy for locally advanced rectal cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Capecitabine
irinotecan sucrosofate